Fax: (713) 794-4297
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase
Comparison with historic data
Article first published online: 3 NOV 2003
Copyright © 2003 American Cancer Society
Volume 98, Issue 12, pages 2636–2642, 15 December 2003
How to Cite
Kantarjian, H. M., O'Brien, S., Cortes, J., Giles, F. J., Rios, M. B., Shan, J., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Verstovsek, S., Wierda, W., Keating, M. and Talpaz, M. (2003), Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase. Cancer, 98: 2636–2642. doi: 10.1002/cncr.11831
- Issue published online: 4 DEC 2003
- Article first published online: 3 NOV 2003
- Manuscript Accepted: 5 SEP 2003
- Manuscript Revised: 26 AUG 2003
- Manuscript Received: 27 JUN 2003
- Betty Foster Leukemia Research Fund
- chronic myelogenous leukemia (CML);
- Philadelphia chromosome (Ph);
- imatinib mesylate therapy;
The International Randomized study of Interferon-alpha plus cytarabine (IFN-α plus ara-C) versus STI571 (imatinib mesylate) [IRIS trial] in patients with newly diagnosed Philadelphia chromosome (Ph)-positive, chronic-phase chronic myelogenous leukemia (CML) has not shown (to date) a survival advantage for imatinib. This was most likely because approximately 90% of patients receiving IFN-α plus ara-C changed to imatinib therapy after a median of 8 months into therapy.
The authors analyzed the results with imatinib therapy in patients with newly diagnosed Ph-positive CML in chronic phase and compared their outcome with patients who received IFN-α regimens. A total of 187 patients with Ph-positive CML in early chronic phase treated with imatinib were compared with a historic group of 650 similar patients treated with IFN-α regimens from 1982 until 1997.
Patients who received imatinib were significantly older and had significantly more bone marrow basophilia and less leukocytosis. The complete cytogenetic response (Ph 0%) rates were better with imatinib (81% vs. 32%; P < 0.001), as were the survival rates (30-month estimated survival rates 98% vs. 88%; P = 0.01). A multivariate analysis of the total study group of 837 patients identified imatinib therapy to be a significant independent favorable prognostic factor for survival (P = 0.01).
The current study is the first to indicate the survival advantage of imatinib compared with IFN-α, the previous standard of care, in patients with early chronic-phase CML. Cancer 2003;98:2636–42. © 2003 American Cancer Society.